|
X-linked centronuclear myopathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our previous work on a canine model of XLMTM showed that a single rAAV8-cMTM1 systemic infusion corrected structural abnormalities within the muscle and restored contractile function, with affected dogs surviving more than 4 years post injection.
|
31784415 |
2020 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Recently, we identified an alternatively spliced protein isoform, CMTM1-v5, which is significantly associated with tumor development and could serve as a potential therapeutic drug for lymphoma.
|
31542285 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
31 pairs of tumor tissues before and after NAC and 78 resected tumor tissues after NAC were utilized for immunohistochemistry (IHC) staining of CMTM1_v17 protein.
|
28129775 |
2017 |
|
X-linked centronuclear myopathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
A recombinant adeno-associated virus serotype 8 (rAAV8) vector expressing canine myotubularin (cMTM1) under the muscle-specific desmin promoter (rAAV8-cMTM1) was administered by simple peripheral venous infusion in XLMTM dogs at 10 weeks of age, when signs of the disease are already present.
|
28237839 |
2017 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, our study provides a proof-to-concept that supports the use of CMTM1-v5 to treat lymphoma.
|
31542285 |
2019 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, our study provides a proof-to-concept that supports the use of CMTM1-v5 to treat lymphoma.
|
31542285 |
2019 |
|
Childhood Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, our study provides a proof-to-concept that supports the use of CMTM1-v5 to treat lymphoma.
|
31542285 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Next, we detected CMTM1_v17 expression to confirm correlation between this protein status and clinical characteristics in 78 NSCLC patients with NAC treatment.
|
28129775 |
2017 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our data thus suggest CMTM1 and 3 as priority targets in glioblastomas.
|
25931111 |
2015 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets.
|
25931111 |
2015 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets.
|
25931111 |
2015 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets.
|
25931111 |
2015 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
We propose that CMTM1_v17 may be a novel potential target for therapy in breast cancer patients.
|
25175386 |
2014 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings also have implications for clinical practice as they highlight the potential for therapeutic targeting of CMTM1_v17 for the treatment of breast and other cancers in which CMTM1_v17 impacts cellular proliferation and survival.
|
25175386 |
2014 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We propose that CMTM1_v17 may be a novel potential target for therapy in breast cancer patients.
|
25175386 |
2014 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In the present study, we detected CMTM1_v17 expression in multiple human normal and tumor tissues and found that CMTM1_v17 was highly expressed in testis and many tumor tissues including breast tumor.
|
25175386 |
2014 |